These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31071076)

  • 1. An integrative transcriptome analysis framework for drug efficacy and similarity reveals drug-specific signatures of anti-TNF treatment in a mouse model of inflammatory polyarthritis.
    Karagianni N; Kranidioti K; Fikas N; Tsochatzidou M; Chouvardas P; Denis MC; Kollias G; Nikolaou C
    PLoS Comput Biol; 2019 May; 15(5):e1006933. PubMed ID: 31071076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior
    Ubah OC; Steven J; Porter AJ; Barelle CJ
    Front Immunol; 2019; 10():526. PubMed ID: 30967865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [TNF inhibitors].
    Kameda H
    Nihon Rinsho; 2016 Jun; 74(6):957-62. PubMed ID: 27311185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.
    Póliska S; Besenyei T; Végh E; Hamar A; Pusztai A; Váncsa A; Bodnár N; Szamosi S; Csumita M; Kerekes G; Szabó Z; Nagy Z; Szűcs G; Szántó S; Zahuczky G; Nagy L; Szekanecz Z
    Arthritis Res Ther; 2019 Apr; 21(1):94. PubMed ID: 30987671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
    Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
    J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.
    Kronthaler U; Fritsch C; Hainzl O; Seidl A; da Silva A
    Expert Opin Biol Ther; 2018 Aug; 18(8):921-930. PubMed ID: 29962245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral Tumor Necrosis Factor-Alpha (TNF-α) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice.
    Paouri E; Tzara O; Kartalou GI; Zenelak S; Georgopoulos S
    J Neurosci; 2017 May; 37(20):5155-5171. PubMed ID: 28442538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Levin AD; Wildenberg ME; van den Brink GR
    J Crohns Colitis; 2016 Aug; 10(8):989-97. PubMed ID: 26896086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
    Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
    Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G
    BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic network analysis reveals key drivers of response to anti-TNF biologics in patients with rheumatoid arthritis.
    Yu CY; Lee HS; Joo YB; Cho SK; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Bae SC; Kim K; Bang SY
    Rheumatology (Oxford); 2024 May; 63(5):1422-1431. PubMed ID: 37572297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.